The New England Journal of Medicine (NEJM) RSS feed -- Search Results in Cardiology. NEJM (https://www.nejm.org) is a weekly general medical journal that publishes new medical research findings, review articles, and editorial opinion on a wide variety of topics of importance to biomedical science and clinical practice. https://www.nejm.org/action/showPodcastsFeeds NEJM Group Mon, 02 Nov 2026 10:17:24 GMT 2026 NEJM Group en-us 1440 In a randomized trial, CCTA-guided PCI with structured preprocedural planning and intraprocedural guidance was noninferior to intravascular ultrasound–guided PCI with respect to target-vessel failure at 12 months. https://www.nejm.org/doi/full/10.1056/NEJMoa2610771?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2610771 Carlos Collet, Takuya Mizukami, Frederic Bouisset, Gianluca Pontone, Carlo Zivelonghi, Daniel A. Jones, Adriaan Wilgenhof, Nicolaj Brejnholt Støttrup, Bálint Szilveszter, Kaoru Tanaka, Gianluca Mincione, Yader Sandoval, Ian Purcell, James C. Spratt, Divaka Perera, Niels Thue Olsen, Tetsuya Amano, Peter O’Kane, Simone Biscaglia, Hasan Jilaihawi, Ziad Ali, Eric Van Belle, Richard Good, Taito Arai, Brian Ko, Jeroen Sonck, Alan Bagnall, Timothy Fairbairn, Antonio Bartorelli, Giulio Stefanini, Jonathon Leipsic, Thomas Engstrøm, Bjarne Linde Nørgaard, Bernard De Bruyne, Bruno R. da Costa, Daniele Andreini, the P4 Trial Investigators* 2026-11-01 Coronary CT Angiography versus Intravascular Ultrasound Guidance for PCI In patients with atrial fibrillation and a stent placed at least 1 year earlier, non–vitamin K antagonist oral anticoagulant monotherapy resulted in fewer net adverse clinical events at 2 years than a NOAC plus clopidogrel. https://www.nejm.org/doi/full/10.1056/NEJMc2612608?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMc2612608 Sang-Hyup Lee, Yong-Joon Lee, Jung Ho Heo, Sung Gyun Ahn, Sanghoon Shin, Joon-Hyung Doh, Ae-Young Her, Byung-Ryul Cho, Gwang-Sil Kim, Taek-Geun Kwon, Sang-Wook Lim, Jaemin Shim, Ji-Yong Jang, Kyounghoon Lee, Yun-Hyeong Cho, Cheol Ung Choi, Sang-Rok Lee, Hyung-Bok Park, Han Cheol Lee, Seunghwan Kim, Kyeong Ho Yun, Jong-Hwa Ahn, Byoung-Kwon Lee, Deok-Kyu Cho, Song-Yi Kim, Ung Kim, Tae Soo Kang, Seong Huan Choi, Won-Ho Kim, Jin Bae Lee, Moo-Yong Rhee, Jin-Bae Kim, Sang-Ho Jo, Dae Woo Hyun, Daehoon Kim, Seung-Jun Lee, Hee Tae Yu, Sung-Jin Hong, Jae-Sun Uhm, Dong-Ho Shin, Chul-Min Ahn, Byeong-Keuk Kim, Boyoung Joung, Young-Guk Ko, Hui-Nam Pak, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jang, Tae-Hoon Kim, Jung-Sun Kim, for the ADAPT AF-DES Investigators* 2026-10-31 Extended Outcomes of the ADAPT AF-DES Trial Among patients with syncope that remained unexplained after evaluation in the ED, immediate initiation of 14-day ECG monitoring did not result in significantly fewer patient-reported syncope episodes at 1 year than standard care. https://www.nejm.org/doi/full/10.1056/NEJMoa2605812?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2605812 Matthew J. Reed, Steve Goodacre, Christopher J. Weir, Lynn Dinsmore, Amy Nugent, Titouan Kennel, Christopher C. Lang, Neil R. Grubb, Praveen Thokala, Karen Kilcoyne, Rachel O’Brien, Caroline Blackstock, Shona McDonald, Nicola Freeman, Ellise Clarke, Imad Adamestam, Louise Taylor, the ASPIRED Investigators* 2026-10-29 Immediate Ambulatory Electrocardiographic Monitoring in Syncope An oncology fellow is used to having code-status discussions with patients and families, but when her father is downed by an ocean wave, she suddenly sees the DNR question from a new perspective. https://www.nejm.org/doi/full/10.1056/NEJMp2605919?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMp2605919 Netana Markovitz 2026-10-29 My Father’s Code Syncope is a commonly encountered clinical entity, with prevalence as high as 20 to 40% in the general population.1 Although syncope is generally benign, a small subgroup of patients will have a clinically important cardiac arrhythmia.2,3 These arrhythmias are not easily diagnosed but can be detected... https://www.nejm.org/doi/full/10.1056/NEJMe2612346?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2612346 Marc A. Probst 2026-10-29 Cardiac Monitors for Unexplained Syncope — More Benefit than Expected? Among patients with mild stroke from large-vessel occlusion, 69.4% had a favorable functional outcome at 90 days with endovascular therapy plus medical management, as compared with 50.0% with medical management alone. https://www.nejm.org/doi/full/10.1056/NEJMoa2609149?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2609149 Jianmin Liu, Tingyu Yi, Pengfei Xing, Meihua Wu, Liyong Zhang, Tuanyuan Zheng, Mingzhu Huang, Yanmin Wu, Hao Wang, Guoyong Zeng, Jinglun Li, Ya Peng, Yueqi Zhu, Yibin Fang, Xueli Cai, Jun Luo, Yuanbiao Lei, Hao Qin, Pu Fang, Yamei Tang, Guangxiong Yuan, En Wang, Xiongjun He, Xiongwei Lu, Zhentao Li, Bo Lei, Hua Cao, Xinguang Yang, Chenghua Xu, Meixia Shang, Craig S. Anderson, Zeguang Ren, Pengfei Yang, Wenhuo Chen, the MILD-MT Investigators* 2026-10-23 Trial of Endovascular Therapy for Mild Stroke with Large-Vessel Occlusion Among patients with salvageable tissue 24 to 72 hours after stroke, physical function at 90 days was better with thrombectomy than with medical care alone, but intracerebral hemorrhage and death were more common with thrombectomy. https://www.nejm.org/doi/full/10.1056/NEJMoa2609362?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2609362 Pengfei Yang, Hongjian Shen, Tingyu Yi, Pengfei Xing, Junfeng Su, Changming Wen, Weiyi Zhong, Qiang Li, Yunting He, Xiaoying Chen, Song He, Xinwen Ren, Shoujiang You, Yang Zhao, Borui Wang, Yongxin Zhang, Lei Chen, Xuan Zhu, Minmin Zhang, Ying Yu, Yi Jiang, Yina Wu, Chuanchuan Wang, Xiaoxi Zhang, Wenjin Yang, Fang Shen, Lijun Wang, Meihua Huyan, Bing Tian, Wenhuo Chen, Guangxian Nan, Liyong Zhang, Huaizhang Shi, Jianfeng Han, Tong Li, Fan Zhang, Ming Wei, Chenghua Xu, Ya Peng, Jun Sun, Shouchun Wang, Hongxing Han, Hao Wang, Wenqiang Cai, Meng Zhang, Congguo Yin, Guangsen Cheng, Rong Yin, Quanbin Zhang, Guodong Xiao, Yunfeng Zhang, Sheng Liu, Hui Li, Lei Zhang, Zifu Li, Yu Zhou, Rui Zhao, Qiang Li, Charles B.L.M. Majoie, Lili Song, Yongwei Zhang, Craig S. Anderson, Jianmin Liu, the LATE-MT Investigators* 2026-10-23 Mechanical Thrombectomy 24 to 72 Hours after Large-Vessel Ischemic Stroke In 2015, pivotal randomized, controlled trials established the benefit of endovascular treatment for acute ischemic stroke due to a large-vessel occlusion.1,2 The trials showed a major clinical benefit in patients presenting with relatively standard stroke features: large-vessel occlusion in the anterior circulation; relevant clinical neurologic deficit; short time... https://www.nejm.org/doi/full/10.1056/NEJMe2612692?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2612692 Gaultier Marnat 2026-10-23 Expanding the Evidence and Indications for Thrombectomy in Ischemic Stroke Among adults with endocarditis caused by S. aureus, E. faecalis, or streptococcus species, tailored-duration antibiotic therapy led to 13 more days alive without antibiotics than standard therapy, but with a higher incidence of relapse. https://www.nejm.org/doi/full/10.1056/NEJMoa2607887?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2607887 Henning Bundgaard, Mia Pries-Heje, Julie Hjulmand, Rasmus Hasselbalch, Peter Godsk Jørgensen, Søren Fanø, Nana Køber, Christian Tuxen, Nareen Kader, Ekim Seven, Lars Ege Rasmussen, Malene Wienberg, Niels Eske Bruun, Marlene Tofterup, Magnus Rasmussen, Lindsey R. Baden, Ann Woolley, Theis Lange, Jannik Helweg-Larsen, Jonas Agerlund Povlsen, Emil Fosbøl, Claus Moser, Kasper Iversen, the POET II Investigators* 2026-10-22 Response-Tailored or Standard-Duration Antibiotic Treatment for Infective Endocarditis Adding milvexian to standard antiplatelet therapy after an acute coronary syndrome event did not lower the risk of a composite of cardiovascular death, MI, or ischemic stroke but did not increase intracranial or fatal bleeding. https://www.nejm.org/doi/full/10.1056/NEJMoa2608717?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2608717 C. Michael Gibson, P. Gabriel Steg, M. Cecilia Bahit, Rasha Al-Lamee, Shamir R. Mehta, Roxana Mehran, Jeffrey I. Weitz, Shinya Goto, Jose Carlos Nicolau, Renato D. Lopes, Junbo Ge, Nebojsa Tasic, Dominick J. Angiolillo, Suzanne J. Baron, Ajay J. Kirtane, Denis Xavier, Satoshi Yasuda, Basil S. Lewis, Duk-Woo Park, Jan H. Cornel, Thomas W. Johnson, Jaroslaw Trebacz, Daniel Duerschmied, Christoph Bode, Bela Merkely, Maria Dorobantu, Dragos Vinereanu, Zuzana Motovska, Hector Bueno, Jose Luis Lopez-Sendon, Gregory Ducrocq, Giuseppe Ambrosio, Lesley Burgess, Allan Bohm, Chern-En Chiang, Joao Morais, Alan Fong, Umit Guray, Jose Luis Leiva-Pons, Pascal Vranckx, Harvey D. White, Sasko Kedev, Marco Valgimigli, Duško Cerovec, Dimitris Tousoulis, Gemma Figtree, Thuong Dung Ho, Rody G. Sy, Morten Bøttcher, Kurt Huber, Rimvydas Slapikas, Andrejs Erglis, Jack Wei Chieh Tan, Christian Pincetti, Karen S. Pieper, Kenneth W. Mahaffey, Carolyn S.P. Lam, S. Claiborne Johnston, Graeme J. Hankey, Jennifer S. Li, Luke Zheng, Ronald Aronson, Danshi Li, Ravi Notani, Philippe Vieira Pires, Thomas J. Povsic, Alistair C. Lindsay, Alexei Plotnikov, Hsiaowei Deng, Elliot S. Barnathan, Robert A. Harrington, the LIBREXIA ACS Committees and Investigators* 2026-10-22 Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event Infective endocarditis has traditionally been treated with intravenous antimicrobial agents for a defined number of weeks.1 Clinicians have been understandably reluctant to use oral antimicrobial therapy or truncate the duration of treatment owing to one universally feared and potentially lethal complication: relapse of infection. In fact, no randomized... https://www.nejm.org/doi/full/10.1056/NEJMe2612352?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2612352 Daniel C. DeSimone, Larry M. Baddour 2026-10-22 Infective Endocarditis — When Is Enough Enough? Despite the receipt of guideline-directed medical therapies and potent antiplatelet agents, patients who have had an acute coronary syndrome event are at increased risk for a recurrent ischemic event.1,2 Considerable interest has been focused on the addition of anticoagulation to further mitigate ischemic risk in such patients. More... https://www.nejm.org/doi/full/10.1056/NEJMe2612343?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2612343 Debabrata Mukherjee 2026-10-22 Role for Factor XIa Inhibitors after an Acute Coronary Syndrome Event This video roundtable explores the history, rationale, process, and effects of eliminating the inappropriate and inequitable use of race in clinical algorithms. https://www.nejm.org/doi/full/10.1056/NEJMp2612470?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMp2612470 Helen Burstin, Felicity T. Enders, Sean Levy, Shazia Siddique, Joseph L. Wright, Debra Malina 2026-10-22 Perspective Roundtable: Examining the Use of Race in Clinical Algorithms In patients with severe tricuspid regurgitation and heart failure, transcatheter tricuspid-valve repair plus medical therapy was superior to medical therapy alone in reducing hospitalizations for heart failure and deaths. https://www.nejm.org/doi/full/10.1056/NEJMoa2606934?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2606934 Jörg Hausleiter, Thomas J. Stocker, Tobias Geisler, Philipp Lurz, Wolfgang Rottbauer, Edith Lubos, Niklas Schofer, Christian Frerker, Johanne Frank, Holger Thiele, Rico Osteresch, Volker Rudolph, Alexander Lauten, Erion Xhepa, Jürgen Rothe, Tienush Rassaf, Stephan Baldus, Georg Nickenig, David M. Leistner, Eike Tigges, Victoria Kehl, Mirjam Kessler, Tobias Kister, Tobias Ruf, Muhammed Gerçek, Meinrad Gawaz, Derk Frank, Ingo Eitel, Ralph Stephan von Bardeleben, Daniel Kalbacher, Osama Soliman, Michael Näbauer, Steffen Massberg, the TRIC-I-HF-DZHK24 Investigators* 2026-10-08 Tricuspid-Valve Intervention in Heart Failure The care of patients with valvular heart disease has been revolutionized by three key advances in the field: technological innovation of transcatheter therapies combined with the audacity to try new procedures; a heart team that includes interventional cardiologists, cardiac surgeons, imaging specialists, and, when needed, heart-failure cardiologists working in partnership... https://www.nejm.org/doi/full/10.1056/NEJMe2611648?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2611648 Manesh R. Patel 2026-10-08 Transcatheter Tricuspid-Valve Intervention for Severe Tricuspid Regurgitation In five pediatric heart transplantations, a rapid-recovery technique involving oxygenated preservation enabled the use of donated hearts without reanimation. All recipients had normal biventricular function by day 7. https://www.nejm.org/doi/full/10.1056/NEJMc2607437?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMc2607437 Aaron M. Williams, Swaroop Bommareddi, Kevin C. McGann, Awab Ahmad, John Trahanas, Brian Lima, Tammy Ruth, David W. Bearl, Rachel E. Harris, Ryan D. Byrne, Caroline West, A. Joey Lepore, Phyllis Aycock, Nicole Michaud, Sonya Burrell, Susana A. Stripling, Amir T. Dereshgi, Garrett Coyan, David Bichell, Amanpreet Kalsi, Amy M. Babb, Michael Kuntz, Jessica Clark, Shelley Scholl, Matthew Bacchetta, Ashish S. Shah, Yishay Orr, Carlos M. Mery, Ziv Beckerman 2026-10-08 Pediatric Heart Transplantation with Donation after Circulatory Death In older adults without cardiovascular disease, treatment with atorvastatin led to a lower risk of major cardiovascular events than placebo at a median of 5.9 years but did not result in longer disability-free survival. https://www.nejm.org/doi/full/10.1056/NEJMoa2607314?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2607314 Sophia Zoungas, Rory Wolfe, Chris Moran, Stephen J. Nicholls, Geoffrey C. Cloud, Christopher M. Reid, Andrew M. Τonkin, Lawrence Beilin, Anthony S. Wierzbicki, Trevor T.-J. Chong, Jonathan C. Broder, Andrea J. Curtis, Zachary Flanagan, Ingrid Hopper, Joanne Ryan, Simone Spark, John J. McNeil, Mark R. Nelson, the STAREE Investigators 2026-10-01 Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults For decades, one of the most important unresolved questions in preventive cardiovascular medicine has been whether statin therapy should be initiated for primary prevention in healthy older adults. Although age is among the strongest determinants of absolute risk, the benefits of statin therapy beyond 70 to 75 years of age... https://www.nejm.org/doi/full/10.1056/NEJMe2611127?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2611127 Martin Bødtker Mortensen 2026-10-01 Statins in Older Adults — Evidence at Last In a phase 1a trial, one-time CRISPR-Cas9 gene editing with CTX310 was associated with no treatment-related dose-limiting toxic effects and with sustained reductions in ANGPTL3 and atherogenic lipids at 1 year. https://www.nejm.org/doi/full/10.1056/NEJMc2609825?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMc2609825 Luke J. Laffin, Stephen J. Nicholls, Russell S. Scott, Peter M. Clifton, Renate Koops, Ashish Sarraju, Shweta Singh, Qiuqing Wang, Kathy Wolski, Huansheng Xu, Jen Nielsen, Naimish Patel, Jason M. Duran, Steven E. Nissen 2026-10-01 Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310 In two placebo-controlled trials, oveporexton improved wakefulness, reduced daytime sleepiness, and lowered the cataplexy rate among patients with narcolepsy type 1. Increased urinary frequency and transient insomnia were common. https://www.nejm.org/doi/full/10.1056/NEJMoa2601598?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2601598 Yves Dauvilliers, Emmanuel Mignot, Jakub Antczak, Isabelle Arnulf, Lucie Barateau, Erik Buntinx, Bruce Corser, Alex Iranzo, Ramin Khatami, Gert Jan Lammers, Katharina Lederer, Kristian Bernhard Nilsen, Fabio Pizza, Markus H. Schmidt, Sheila Sivam, Oliver Sum-Ping, Mitsutaka Taniguchi, Shuqin Zhan, Anson Abraham, Alice Cai, Yeting Du, Mark R. Etherton, Helene Faessel, Samuel Hsiao, Harisha Kadali, Elena Koundourakis, Melissa Naylor, Rachel Neuwirth, Tina Olsson, Raquel Rogers, Sarah Sheikh, Shinichiro Tanaka, Philipp von Rosenstiel, Christian von Hehn, Yaming Hang, Baiyun Yao, Rafael del Rio Villegas, Giuseppe Plazzi 2026-09-24 Oveporexton for Narcolepsy Type 1 — Results from Two Phase 3 Trials